Artificial joints are a multi-billion-dollar business that is expected to keep growing as the population ages and orthopedic products continue to evolve. The American Academy of Orthopedic Surgeons recently predicted that the number of hip replacements will nearly triple over the next 25 years.
That's good news for makers of joint replacements, including Stryker Corp. (symbol SYK), which has seen its revenue increase at a 15% compound rate over the last five years. But despite growing demand for orthopedic products, the industry is facing pressure from hospitals that want to cut the cost of orthopedic devices.
Some hospitals are considering banding together to switch to contracted vendors that offer bulk discounts. So far, these arrangements haven't gained footing, but reports predicting slowing growth in the orthopedic device sector have put a damper on stock prices.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Stryker's shares, currently $43, have fallen 9% this year. The company's price-earnings ratio has dropped quite a bit since 2004 -- another indication that the market is no longer knee-jerk enamored of the company.
Even if Stryker isn't able to raise its prices as much as it has in the past, the company's key advantage over competitors is diversification, says a report from Zacks Investment Research, which recently upgraded the stock to a "buy" rating. Of the major orthopedic manufacturers, Stryker is the least directly exposed to the implant market, with joint replacements making up only about a third of sales.
Stryker's other business segments are surgical equipment manufacturing and physical therapy services. In 2005, revenues from surgical-device sales increased 21%, while sales from physical therapy services grew 7%. It also has some research projects in the biotechnology area.
And Stryker adds to its portfolio of products through acquisitions. At the end of 2005, the company bought PlasmaSol, a producer of low-temperature sterilization equipment, for $17.5 million. In March, Stryker struck a $50 million deal to purchase Sightline Technologies, an Israel-based manufacturer of flexible endoscopes. The buying spree will likely continue. "Stryker's balance sheet is in excellent condition, so acquisitions are a constant possibility," says the Zacks report.
At $43, Stryker trades at 21 times estimated 2006 profits of $2.02 per share and 18 times estimated 2007 profits, according to Thomson First Call. Zacks' six-month price target for the stock is $53. In 2006, the company expects revenues to grow between 11% and 14% and predicts that earnings will grow at least 20%, its perennial target and the number that's made the company a favorite of growth-stock investors for a long time.
-- Katy Marquardt
-
Stocks Sink with Meta, Microsoft: Stock Market TodayAlphabet was a bright light among the Magnificent 7 stocks today after the Google parent's quarterly revenue topped $100 billion for the first time.
-
The Original Property Tax Hack: Avoiding The ‘Window Tax’Property Taxes Here’s how homeowners can challenge their home assessment and potentially reduce their property taxes — with a little lesson from history.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have TodayBank of America stock has been a massive buy-and-hold bust.
-
If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have TodayORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
How to Invest for Rising Data Integrity RiskAmid a broad assault on venerable institutions, President Trump has targeted agencies responsible for data critical to markets. How should investors respond?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
-
If You'd Put $1,000 Into UnitedHealth Group Stock 20 Years Ago, Here's What You'd Have TodayUNH stock was a massive market beater for ages — until it wasn't.
-
What Tariffs Mean for Your Sector ExposureNew, higher and changing tariffs will ripple through the economy and into share prices for many quarters to come.
-
How to Invest for Fall Rate Cuts by the FedThe probability the Fed cuts interest rates by 25 basis points in October is now greater than 90%.
